メニュー戻る Whitepapers

White Papers

What is a White Paper?

White Papers are written by organizations to explain a specific business practice, service, product or technology, and provide useful information to readers looking to understand this problem and enhance their job performance. There is no standard subject matter or presentation format but White Papers typically present data supported by facts, figures and statistics to explain the problem and its potential solution. They are generally 2500 words long but can be longer if the topic requires more in-depth discussion, and are written in a narrative voice with no quotes.

White Paper Library

Larvol White Paper Podcast

AI-Assisted Tools for Monitoring Precision Medicine Predictive Biomarkers Landscape
Predictive biomarkers, biological characteristics which identify individuals more likely than others to favorably respond to a therapy, are helping to improve accuracy in precision medicine. “Our database creates a detailed real time platform of reliable insights on biomarkers and biomarker activity, used primarily to stay up to date on cancer biomarkers, and to understand the extent to which they're predictive of drug response,” explains Sabrina Bellisario, Director of Operations, Larvol. “Our newest endeavor is to apply artificial intelligence and algorithmic approaches to actually predict new areas of research for particular biomarkers, drugs and tumors,” continues Larvol Director of Oncology Mark Gramling.

Download

Sciformix White Paper

Sciformix Accelerator Methodology Delivers Validated Oracle Argus Cloud in Record Time
Due to various reasons, clinical and post-marketing safety data and information are often housed in disparate and/or legacy systems. This makes it difficult to access and view data, make informed decisions, and manage reporting to regulatory authorities. In addition, safety data is managed at different levels of effectiveness, which results in a lack of control. Organizations look to implement a consistent, validated, and secure Best-of-breed safety solution, yet oftentimes they don’t have the resources (money, expertise, etc.) to maintain the infrastructure in-house. The Sciformix Accelerator Methodology can be used to implement a validated, compliant, secure and hassle-fee Oracle Argus Cloud safety solution in record time.

Download

Clinical Ink White Paper

eSource: Reducing Site Workload for Better, Faster, Safer Clinical Trials
Life science companies are under increasing pressure to execute clinical trials faster with higher quality. As a result, more sponsors and CROs are looking for new ways to better leverage investigative site relationships to improve clinical trial performance. To this end, some clinical organizations have adopted electronic source (eSource) to help improve study quality and efficiency - for both sponsor and site. Unlike traditional electronic data capture (EDC), Clinical Ink's eSource platform SureSource was designed to minimize clinical trial complexity for site users. Clinical Ink's Site Impact Survey provides scientific evidence regarding the impact of SureSource from 517 site users. Results confirm that SureSource significantly reduces workload, lessens queries, and improves data quality compared to paper and EDC.

Download

Wincere White Paper

Compliance for Mobile Medical Apps
There is not yet a single device that can diagnose, monitor, and treat a patient for every type of health problem without even making physical contact or directly interacting with body molecules. That’s still something of a holy grail in the medical device industry. What we have instead is the birth of the first generation of a new species, burst from the womb of rapidly evolving technology; tens of thousands of medical devices and mobile apps designed for uniquely specific purposes; all working together to lay the collective foundation for what could one day be the ultimate medical utopia. But without discipline, all this forward momentum is for naught. As tempting as it is to run wild with ideas and succumb to the raptures of pure creativity, progress must be tempered by responsibility. Chaos benefits no one.

Download

MediciGlobal White Paper

Clinical Trial Retention Meta-Analysis: Subjects that are actively or passively enrolled into clinical trials are retained differently
Patient recruitment methods can have a significant effect on the retention of subjects in clinical trials; these effects can result in considerable cost implications. Subjects that actively sought clinical trial involvement through an online pre-screener (in response to online clinical trial advertising) using the Medici Global model, showed 38% lower relative risk of drop out across four studies compared to those who were recruited by sites, with divergence across visits in all four studies. Since increasing sample size is typically associated with an increase in the statistical power of the study, the loss of subjects over the course of a trial can result in missed endpoints and negatively impact the outcome of the study. Engaging subjects that actively seek clinical trial participation results in a reduction of study withdrawals or patient dropout rates; the effect of which eliminates the need for over-enrollment of patients to offset expected retention loss. Increased retention rates accelerate enrollment timelines and result in saving time and money.

Download

Interested in publishing?

For more information on publishing your White Paper with DIA, including schedule and pricing, please contact:

Send Email

+1.202.351.1925

White Papers

What is a White Paper?

White Paper Library

Interested in publishing?

最新情報や機会を逃さないで